Thiocarboxamide derivatives

ABSTRACT

Compounds of formula (1):                    
     wherein 
     R 1  is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; 
     Alk 1  is an optionally substituted aliphatic or heteroaliphatic chain; 
     L 1  is a linker atom or group; 
     r and s is each zero or an integer 1; 
     R 2  and R 3 , which may be the same or different, is each a hydrogen or halogen atom or a straight or branched alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl or nitro group; 
     Alk 2  is a straight or branched alkylene chain; 
     m is zero or an integer 1; 
     R 4  is a hydrogen atom or a methyl group; 
     R 5  is a hydrogen atom or a straight or branched alkyl group; 
     R 6  is a group —(CH 2 ) t R 7  in which t is zero or the integer 1 and R 7  is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; 
     R is a carboxylic acid (—CO 2 H) or a derivative thereof; 
     and the salts, solvates and hydrates thereof are described. 
     The compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

This invention relates to a series of thioamides, to compositions containing them, to processes for their preparation, and to their use in medicine.

Over the last few years it has become increasingly clear that the physical interaction of inflammatory leukocytes with each other and other cells of the body plays an important role in regulating immune and inflammatory responses [Springer, T A. Nature, 346,425, (1990); Springer, T. A. Cell 76, 301, (1994)]. Many of these interactions are mediated by specific cell surface molecules collectively referred to as cell adhesion molecules.

The adhesion molecules have been sub-divided into different groups on the basis of their structure. One family of adhesion molecules which is believed to play a particularly important role in regulating immune and inflammatory responses is the integrin family. This family of cell surface glycoproteins has a typical non-covalently linked heterodimer structure. At least 14 different integrin alpha chains and 8 different integrin beta chains have been identified [Sonnenberg, A. Current Topics in Microbiology and Immunology, 184, 7, (1993)]. The members of the family are typically named according to their heterodimer composition although trivial nomenclature is widespread in this field. Thus the integrin termed α4β1 consists of the integrin alpha 4 chain associated with the integrin beta 1 chain, but is also widely referred to as Very Late Antigen 4 or VLA4. Not all of the potential pairings of integrin alpha and beta chains have yet been observed in nature and the integrin family has been subdivided into a number of subgroups based on the pairings that have been recognised [Sonnenberg, A. ibid].

The importance of cell adhesion molecules in human leukocyte function has been further highlighted by a genetic deficiency disease called Leukocyte Adhesion Deficiency (LAD) in which one of the families of leukocyte integrins is not expressed [Marlin, S. D. et al J. Exp. Med. 164, 855 (1986)]. Patients with this disease have a reduced ability to recruit leukocytes to inflammatory sites and suffer recurrent infections which in extreme cases may be fatal.

The potential to modify adhesion molecule function in such a way as to beneficially modulate immune and inflammatory responses has been extensively investigated in animal models using specific monoclonal antibodies that block various functions of these molecules [e.g. Issekutz, T. B. J. Immunol. 3394, (1992); Li, Z. et al Am. J. Physiol. 263, L723, (1992); Binns, R. M. et al J. Immunol. 157, 4094, (1996)]. A number of monoclonal antibodies which block adhesion molecule function are currently being investigated for their therapeutic potential in human disease.

One particular integrin subgroup of interest involves the α4 chain which can pair with two different beta chains β1 and β7 [Sonnenberg, A. ibid]. The α4β1 pairing occurs on many circulating leukocytes (for example lymphocytes, monocytes and eosinophils) although it is absent or only present at low levels on circulating neutrophils. α4β1 binds to an adhesion molecule (Vascular Cell Adhesion Molecule-1 also known as VCAM-1) frequently up-regulated on endothelial cells at sites of inflammation [Osborne, L. Cell, 62, 3, (1990)]. The molecule has also been shown to bind to at least three sites in the matrix molecule fibronectin [Humphries, M. J. et al. Ciba Foundation Symposium, 189, 177, (1995)]. Based on data obtained with monoclonal antibodies in animal models it is believed that the interaction between α4β1 and ligands on other cells and the extracellular matrix plays an important role in leukocyte migration and activation [Yednock, T. A. et al, Nature, 356, 63, (1992); Podolsky, D. K. et al. J. Clin. Invest. 92, 373, (1993); Abraham, W. M. et al. J. Clin. Invest. 93, 776, (1994)].

The integrin generated by the pairing of α4 and β7 has been termed LPAM-1 [Holzmann, B and Weissman, I. EMBO J. 8, 1735, (1989)] and like α4β1, binds to VCAM-1 and fibronectin. In addition, α4β7 binds to an adhesion molecule believed to be involved in the homing of leukocytes to mucosal tissue termed MAdCAM-1 [Berlin, C. et al, Cell, 74, 185, (1993)]. The interaction between α4β7 and MAdCAM-1 may also be important at sites of inflammation outside of mucosal tissue [Yang, X-D. et al, PNAS, 91, 12604(1994)].

Regions of the peptide sequence recognised by α4β1 and α4β7 when they bind to their ligands have been identified. α4β1 seems to recognise LDV, IDA or REDV peptide sequences in fibronectin and a QIDSP sequence in VCAM-1 [Humphries, M. J. et al, ibid] whilst α4β7 recognises a LDT sequence in MAdCAM-1 [Briskin, M. J. et al, J. Immunol. 156, 719, (1996)]. There have been several reports of inhibitors of these interactions being designed from modifications of these short peptide sequences [Cardarelli, P. M. et al J. Biol. Chem. 269, 18668, (1994); Shroff, H. N. Bioorganic. Med. Chem. Lett. 6, 2495, (1996); Vanderslice, P. J. Immunol. 158, 1710, (1997)]. It has also been reported that a short peptide sequence derived from the α4β1 binding site in fibronectin can inhibit a contact hypersensitivity reaction in a trinitrochlorobenzene sensitised mouse [Ferguson, T. A. et al, PNAS 88, 8072, (1991)].

Since the alpha 4 subgroup of integrins are predominantly expressed on leukocytes their inhibition can be expected to be beneficial in a number of immune or inflammatory disease states. However, because of the ubiquitous distribution and wide range of functions performed by other members of the integrin family it is very important to be able to identify selective inhibitors of the alpha 4 subgroup.

We have now found a group of compounds which are potent and selective inhibitors of α4 integrins. Members of the group are able to inhibit α4 integrins such as α4β1 and/or α4β7 at concentrations at which they generally have no or minimal inhibitory action on α integrins of other subgroups. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described hereinafter.

Thus according to one aspect of the invention we provide a compound of formula (1)

wherein

R¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain;

L¹ is a linker atom or group;

r and s is each zero or an integer 1;

R² and R³, which may be the same or different, is each a hydrogen or halogen atom or a straight or branched alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl or nitro group;

Alk² is a straight or branched alkylene chain;

m is zero or an integer 1;

R⁴ is a hydrogen atom or a methyl group;

R⁵ is a hydrogen atom or a straight or branched alkyl group;

R⁶ is a group —(CH₂)_(t)R⁷ in which t is zero or the integer 1 and R⁷ is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

R is a carboxylic acid (—CO₂H) or a derivative thereof; and the salts, solvates and hydrates thereof.

It will be appreciated that compounds of formula (1) may have one or more chiral centres. Where one or more chiral centres is present, enantiomers or diastereomers may exist, and the invention is to be understood to extend to all such enantiomers, diasteromers and mixtures thereof, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise.

In the compounds of formula (1), derivatives of the carboxylic acid group R include carboxylic acid esters and amides. Particular esters and amides include those —CO₂Alk⁵, —CONH₂, —CONHR¹² and —CON[R¹²]₂ groups described below in relation to the group R⁷.

Alk² in the compounds of the invention may be for example a straight or branched C₁₋₃alkylene chain. Particular examples include —CH₂—, —CH(CH₃)— and —(CH₂)₂—.

When R⁵ in the compounds of formula (1) is a straight or branched alkyl group it may be a straight or branched C₁₋₆alkyl group, e.g. a C₁₋₃alkyl group such as a methyl or ethyl group.

When in the compounds of the invention L¹ is present as a linker atom or group it may be any divalent linking atom or group. Particular examples include —O— or —S— atoms or —C(O)—, —C(O)O—, —C(S)—, —S(O)—, —S(O)₂—, —N(R⁸)— [where R⁸ is a hydrogen atom or an optionally substituted alkyl group], —CON(R⁸)—, —OC(O)N(R⁸)—, —CSN(R⁸)—, —N(R⁸)CO—, —N(R⁸)C(O)O—, —N(R⁸)CS—, —S(O)₂N(R⁸)—, —N(R⁸)S(O)₂—, —N(R⁸)CSN(R8)—, -or —N(R⁸)SO₂N(R⁸)— groups. Where the linker group contains two R⁸ substituents, these may be the same or different.

When Alk¹ in compounds of formula (1) is an optionally substituted aliphatic chain it may be an optionally substituted C₁₋₁₀ aliphatic chain. Particular examples include optionally substituted straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl chains.

Heteroaliphatic chains represented by Alk¹ include the aliphatic chains just described but with each chain additionally containing one, two, three or four heteroatoms or heteroatom-containing groups. Particular heteroatoms or groups include atoms or groups L² where L² is as defined above for L¹ when L¹ is a linker atom or group. Each L² atom or group may interrupt the aliphatic chain, or may be positioned at its terminal carbon atom to connect the chain to an adjoining atom or group.

Particular examples of aliphatic chains represented by Alk¹ include optionally substituted —CH₂—, —CH₂CH₂—, —CH(CH₃)—, —C(CH₃)₂, —(CH₂)₂CH₂—, —CH(CH₃)CH₂—, —(CH₂)₃CH₂—, —CH(CH₃)CH₂CH₂—, —CH₂CH(CH₃)CH₂—, —C(CH₃)₂CH₂—, —(CH₂)₄CH₂—, —(CH₂)₅CH₂—, —CHCH—, —CHCHCH₂—, —CH₂ CHCH—, —CHCHCH₂CH₂—, —CH₂ CHCHCH₂—, —(CH₂)₂CHCH—, —CC—, —CCCH₂—, —CH₂CC—, —CCCH₂CH₂—, —CH₂CCCH₂—, or —(CH₂)₂CC— chains. Where appropriate each of said chains may be optionally interrupted by one or two atoms and/or groups L² to form an optionally substituted heteroaliphatic chain. Particular examples include optionally substituted —L²CH₂—, —CH₂L²CH₂—, —L²(CH₂)₂—, —CH₂L²(CH₂)₂—, —(CH₂)₂L²CH₂—, —L²(CH₂)₃— and —(CH₂)₂L²(CH₂)₂— chains.

The optional substituents which may be present on aliphatic or heteroaliphatic chains represented by Alk¹ include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkoxy, e.g. methoxy or ethoxy, thiol, C₁₋₆alkylthio e.g. methylthio or ethylthio, amino or substituted amino groups. Substituted amino groups include —NHR⁹ and —N(R⁹)₂ groups where R⁹ is an optionally substituted straight or branched alkyl group as defined above for R⁵. Where two R⁹ groups are present these may be the same or different. Particular examples of substituted chains represented by Alk¹ include those specific chains just described substituted by one, two, or three halogen atoms such as fluorine atoms, for example chains of the type —CH(CF₃)—, —C(CF₃)₂— —CH₂CH(CF₃)—, —CH₂C(CF₃)₂—, —CH(CF₃)— and —C(CF₃)₂CH₂.

Optionally substituted heterocycloaliphatic groups represented by R⁷ include optionally substituted C₃₋₁₀heterocycloaliphatic groups. Particular examples include optionally substituted C₃₋₁₀heterocycloalkyl, e.g. C₃₋₇ heterocycloalkyl or C₃₋₁₀heterocycloalkenyl, e.g. C₃₋₇hetercycloalkenyl groups, each of said groups containing one, two, three or four heteroatoms or heteroatom-containing groups L² as just defined.

Optionally substituted polycycloaliphatic groups represented by R⁷ include optionally substituted C₇₋₁₀bi- or tricycloalkyl or C₇₋₁₀bi- or tricycloalkenyl groups. Optionally substituted polyheterocycloaliphatic groups represented by R⁷ include the optionally substituted polycycloalkyl groups just described, but with each group additionally containing one, two, three or four L³ atoms or groups.

Particular examples of R⁷ polycycloaliphatic, heterocycloaliphatic and polyheterocycloaliphatic groups include optionally substituted adamantyl, norbornyl, norbornenyl, tetrahydrofuranyl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, pyrrolidinone, oxazolidinyl, oxazolidinone, dioxolanyl, e.g. 1,3-dioxolanyl, imidazolinyl, e.g. 2-imidazolinyl, imidazolidinyl, pyrazolinyl, e.g. 2-pyrazolinyl, pyrazolidinyl, pyranyl, e.g. 2- or 4-pyranyl, piperidinyl, piperidinone, 1,4-dioxanyl, morpholinyl, morpholinone, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, oxazinyl, e.g. 2H-1,3,6H-1,3-6H-1,2-, 2H-1,2- or 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, isoxazinyl, e.g. o- or p-isoxazinyl, oxathiazinyl, e.g. 1,2,5 or 1,2,6-oxathiazinyl, or 1,3,5,-oxadiazinyl groups.

The optional substituents which may be present on the R⁷ polycyclo-aliphatic, heterocycloaliphatic or polyheterocycloaliphatic groups include one, two, three or more substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁₋₆alkoxy, e.g. methoxy or ethoxy, thiol, C₁₋₆alkylthio e.g. methylthio or ethylthio, amino or substituted amino groups. Substituted amino groups include —NHR⁹ and —N(R⁹)₂ groups where R⁹ is as defined above. Additionally, when R⁷ is a heterocycloaliphatic group containing one or more nitrogen atoms each nitrogen atom may be optionally substituted by a group —(L³)_(p)(Alk³)_(q)R¹⁰ in which L³ is —C(O)—, —C(O)O—, —C(S)—, —S(O)₂—, —CON(R⁸)—, —CSN(R⁸)—, —SON(R⁸)— or SO₂N(R⁸)—; p is zero or an integer 1; Alk³ is an optionally substituted aliphatic or heteroaliphatic chain; q is zero or an integer 1; and R¹⁰ is a hydrogen atom or an optionally substituted cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, polyheterocyclo-aliphatic, aromatic or heteroaromatic group.

Optionally substituted aliphatic or heteroaliphatic chains represented by Alk³ include those optionally substituted chains described above for Alk¹.

Optionally substituted cycloaliphatic, heterocycloaliphatic, polycyloaliphatic or polyheterocycloaliphatic groups represented by R¹⁰ include those groups just described for R⁷. Optional substituents which may be present on these groups include those described above in relation to Alk¹ aliphatic and heteroaliphatic chains.

Optionally substituted aromatic or heteroaromatic groups represented by R¹⁰ include those aromatic and heteroaromatic groups generally and specifically described below for R⁷.

In the compounds of formula (1), optionally substituted aromatic groups represented by the group R⁷ and/or R¹⁰ include for example optionally substituted monocyclic or bicyclic fused ring C₆₋₁₂ aromatic groups, such as optionally substituted phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydro-naphthyl, indanyl or indenyl groups .

Optionally substituted heteroaromatic groups, represented by the group R⁷ and/or R¹⁰ in compounds of formula (1) include for example optionally substituted C₁₋₉ heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example nine- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

Particular examples of heteroaromatic groups of these types include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, indolyl, isoindolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5.6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, and imidyl, e.g. succinimidyl, phthalimidyl, or naphthalimidyl such as 1,8-naphthalimidyl.

Optional substituents which may be present on the aromatic or heteroaromatic groups represented by R⁷ and/or R¹⁰ include one, two, three or more substituents, each selected from an atom or group R¹¹ in which R¹¹ is —R^(1a) or -Alk⁴(R¹a)_(m), where R¹¹ a is a halogen atom, or an amino (—NH₂), substituted amino, nitro, cyano, amidino, hydroxyl (—OH), substituted hydroxyl, formyl, carboxyl (—CO₂H), esterified carboxyl, thiol (—SH), substituted thiol, —COR¹² [where R¹² is an -Alk⁴(R^(11a))_(m), aryl or heteroaryl group], —CSR¹², —SO₃H, —SO₂R¹², —SO₂NH₂, —SO₂NHR¹² SO₂N(R¹²)₂, —CONH₂, —CSNH_(2,) —CONHR¹², —CSNHR¹², —CON[R¹²]₂, —CSN(R¹²)₂, —N(R⁸)SO₂R¹², —N(SO₂ R¹²)₂, —N(R⁸)SO₂NH₂, —N(R⁸)SO₂NHR¹², —N(R⁸)SO₂N(R¹²)₂, —N(R⁸)COR¹², —N(R⁸)CON(R¹²)₂, —N(R⁸)CSN(R¹²)₂, —N(R⁸)CSR¹², —N(R⁸)C(O)OR¹², —SO₂NHet¹ [where —NHet¹ is an optionally substituted C₅₋₇cyclicamino group optionally containing one or more other —O— or —S— atoms or —N(R⁸)—, —C(O)— or —C(S)— groups], —CONHet¹, —CSNHet¹, —N(R⁸)SO₂NHet¹, —N(R⁸)CONHet¹, —N(R⁸)CSNHet¹, —SO₂N(R⁸)Het² [where Het² is an optionally substituted monocyclic C₅₋₇carbocyclic group optionally containing one or more —O— or —S— atoms or —N(R⁸)—, —C(O)— or —C(S)— groups], —CON(R⁸)Het², —CSN(R⁸)Het², —N(R⁸)CON(R⁸)Het²,—N(R⁸)CSN(R⁸)Het², aryl or heteroaryl group; Alk⁴ is a straight or branched C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene chain, optionally interrupted by one, two or three —O— or —S— atoms or —S(O)_(n)[where n is an integer 1 or 2] or —N(R¹³)— groups [where R¹³ is a hydrogen atom or C₁₋₆alkyl, e.g. methyl or ethyl group]; and m is zero or an integer 1, 2 or 3. It will be appreciated that when two R⁸ or R¹² groups are present in one of the above substituents, the R⁸ or R¹² groups may be the same or different.

When in the group -Alk⁴(R^(11a))_(mm) is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^(11a) may be present on any suitable carbon atom in -Alk⁴. Where more than one R^(11a) substituent is present these may be the same or different and may be present on the same or different atom in -Alk⁴. Clearly, when m is zero and no substituent R^(11a) is present the alkylene, alkenylene or alkynylene chain represented by Alk⁴ becomes an alkyl, alkenyl or alkynyl group.

When R^(11a) is a substituted amino group it may be for example a group —NHR¹² [where R¹² is as defined above] or a group —N(R¹²)₂ wherein each R¹² group is the same or different.

When R^(11a) is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

When R^(11a) is a substituted hydroxyl or substituted thiol group it may be for example a group —OR¹² or a —SR¹² or —SC(═NH)NH₂ group respectively.

Esterified carboxyl groups represented by the group R^(11a) include groups of formula —CO₂Alk⁵ wherein Alk⁵ is a straight or branched, optionally substituted C₁₋₈alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C₆₋₁₂arylC₁₋₈alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C₆₋₁₂aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C₆₋₁₂aryloxyC₁₋₈alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyl-oxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C₁₋₈alkanoyloxyC₁₋₈alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆₋₁₂aroyloxyC₁₋₈alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxy-propyl group. Optional substituents present on the Alk⁵ group include R^(11a) substituents described above.

When Alk⁴ is present in or as a substituent it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three —O— or —S—, atoms or —S(O)—, —S(O)2— or —N(R⁸)— groups.

Aryl or heteroaryl groups represented by the groups R^(11a) or R¹² include mono- or bicyclic optionally substituted C₆₋₁₂ aromatic or C₁₋₉ heteroaromatic groups as described above for the group R⁷. The aromatic and heteroaromatic groups may be attached to the remainder of the compound of formula (1) by any carbon or hetero e.g. nitrogen atom as appropriate.

When —NHet¹ or -Het² forms part of a substituent R⁷ each may be for example an optionally substituted pyrrolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl group. Additionally Het² may represent for example, an optionally substituted cyclopentyl or cyclohexyl group. Optional substituents which may be present on —NHet¹ or -Het² include those substituents described above in relation to Alk¹ chains.

Particularly useful atoms or groups represented by R¹¹ include fluorine chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl or t-butyl, optionally substituted phenyl, pyridyl, pyrrolyl, furyl, thiazolyl, or thienyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC₁₋₆alkyl, e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio, carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxy-propylthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (—NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminethyl, C₁₋₆dialkylaminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy, e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy, e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, isopropylaminoethoxy, or dimethylaminopropoxy, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, nitro, cyano, amidino, hydroxyl (—OH), formyl [HC(O)—], carboxyl (—CO₂H), —CO₂Alk⁵ [where Alk⁵ is as defined above], C₁₋₆ alkanoyl e.g. acetyl, optionally substituted benzoyl, thiol (—SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, —SC(═NH)NH₂, sulphonyl (—SO₃H), C₁₋₆alkylsulphonyl, e.g. methyl-sulphonyl, aminosulphonyl (—SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (—CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, C₁₋₆alkylaminocabonylC₁₋₆alkylamino, e.g. methylaminocarbonylmethylamino, aminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or ethylaminothiocarbonylamino, C₁₋₆dialkylaminothiocarbonylamino, e.g. dimethylaminothiocarbonylamino or diethylaminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylC₁₋₆alkylamino, e.g. ethylaminothiocarbonylmethylamino, —CONHC(═NH)NH₂, C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, aminosulphonylamino (—NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonyl-amino or ethyl-aminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethyl-aminosulphonylamino or diethylaminosulphonylamino, optionally substituted morpholinesulphonylamino or morpholinesulphonylC₁₋₆alkylamino, optionally substituted phenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, aminoC₁₋₆alkanoylamino e.g. aminoacetylamino, C₁₋₆dialkylaminoC₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino or optionally substituted benzyloxy, pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxycarbonylaminoC₁₋₆alkyl e.g. benzyloxycarbonylaminoethyl, benzothio, pyridylmethylthio or thiazolylmethylthio groups.

Where desired, two R¹¹ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxy group such as methylenedioxy or ethylenedioxy.

It will be appreciated that where two or more R¹¹ substituents are present, these need not necessarily be the same atoms and/or groups. In general, the substituent(s) may be present at any available ring position in the aromatic or heteroaromatic group represented by R⁷.

Alkyl groups represented by the groups R² or R³ in compounds of the invention include for example straight or branched C₁₋₆alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl groups. Alkoxy groups represented by the groups R² or R³ include straight or branched C₁₋₆alkoxy groups such as methoxy or ethoxy groups. Halogen atoms represented by the groups R² or R³ include for example fluorine, chlorine, bromine or iodine atoms. When R² and/or R³ is a haloalkyl or haloalkoxy group it may be for example a haloC₁₋₆alkyl or haloC₁₋₆alkoxy group containing one, two or three halogen atoms selected from fluorine, chlorine, bromine or iodine atoms. Particular examples of groups of this type include —CF₃, —OCF₃, —CCl₃, —OCCl₃, —CHF₂, —OCHF₂, —CHCl₂, —OCHCl₂, —CH₂F, —OCH₂F, —CH₂Cl and —OCH₂Cl groups.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides. alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth met al salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

Generally in the compounds of the invention the group R is preferably a —CO₂H group.

Alk² in compounds of formula (1) is preferably a —CH₂— chain and m is preferably an integer 1.

R⁴ and R⁵ in compounds of the invention is each preferably a hydrogen atom.

In general in compounds of formula (1) -Alk¹L¹- is preferably —CH₂O— or —CON(R⁸)—, particularly —CONH—.

The group R¹ in compounds of formula (1) is preferably an optionally substituted aromatic or heteroaromatic group. Particularly useful groups of these types include optionally substituted phenyl, pyridyl or pyrimidinyl groups.

Particularly useful classes of compounds according to the invention are those wherein R⁶ is a group -R⁷ [i.e. where t is zero] where R⁷ is an optionally substituted heterocycloaliphatic, aromatic or heteroaromatic group as defined herein. Particularly useful groups of this type include optionally substituted C₅₋₇heterocycloaliphatic, especially optionally substituted pyrrolidinyl or thiazolidinyl, optionally substituted phenyl and optionally substituted C₅₋₇heteroaromatic, especially optionally substituted pyridinyl groups. Optional substituents on these groups include in particular R¹¹ atoms or groups where the group is an aromatic or heteroaromatic group and —(L³)_(p)(Alk³)_(q)R¹⁰ groups as described earlier where the group is a nitrogen-containing heterocycloaliphatic group such as a pyrrolidinyl or thiazolidinyl group. Particularly useful —(L³)_(p)(Alk³)_(q)R¹⁰ groups include those in which L³ is a —CO— group. Alk³ in these groups is preferably present (i.e. q is preferably an integer 1) and in particular is a —CH₂— chain. Compounds of this type in which R⁶ is a hydrogen atom or an optionally substituted aromatic or heteroaromatic group, especially an optionally substituted phenyl, pyridyl or imidazolyl group are particularly preferred.

Compounds according to the invention are potent and selective inhibitors of α4 integrins. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.

The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders involving inflammation in which the extravasation of leukocytes plays a role. The invention extends to such uses and to the use of the compounds for preparing a medicament for treating these diseases and disorders. Particular diseases or disorders of this type include inflammatory arthritis such as rheumatoid arthritis vasculitis or polydermatomyositis, multiple sclerosis, allograft rejection, diabetes, inflammatory dermatoses such as psoriasis or dermatitis, asthma and inflammatory bowel disease.

For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100 ng/kg to 100 mg/kg e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration and around 0.05 mg to around 1000 mg e.g. around 0.5 mg to around 1000 mg for nasal administration or administration by inhalation or insufflation.

The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols R, R¹-R⁶, L¹, Alk¹, Alk², m, r and s when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in “Protective Groups in Organic Synthesis”, John Wiley and Sons, 1991]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

Thus according to a further aspect of the invention, a compound of formula (1) in which R is a —CO₂H group may be obtained by hydrolysis of an ester of formula (2):

where R¹³ is an alkyl group.

The hydrolysis may be performed using either an acid or a base depending on the nature of R¹³, for example an organic acid such as trifluoroacetic acid or an inorganic base such as lithium hydroxide optionally in an aqueous organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran or dioxane or an alcohol, e.g. methanol at around ambient temperature. Where desired, mixtures of such solvents may be used.

Intermediate esters of formula (2) may be prepared by treatment of a corresponding ester of formula (3):

with a thiation reagent, such as Lawesson's Reagent, in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.

This reaction may not be particularly suitable with starting materials in which other carbonyl groups are present, for example in L¹ and/or R⁶, and which might undesirably participate in the reaction. To avoid this the reaction with the thiation reagent may be performed earlier in the synthesis of the compound of the invention with an intermediate in which other carbonyl groups are absent and any required carbonyl groups then subsequently introduced by for example acylation as generally described hereinafter.

Esters of formula (3) may be prepared by coupling an amine of formula (4):

or a salt thereof with an acid R⁶CO₂H or an active derivative thereof. Active derivatives of acids include anhydrides, esters and halides.

The coupling reaction may be performed using standard conditions for reactions of this type. Thus for example the reaction may be carried out in a solvent, for example an inert organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a halogenated hydrocarbon, such as dichloromethane, at a low temperature, e.g. around −30° C. to around ambient temperature, optionally in the presence of a base, e.g. an organic base such as an amine, e.g. triethylamine, pyridine, or dimethylaminopyridine, or a cyclic amine, such as N-methylmorpholine.

Where an acid R⁶CO₂H is used, the reaction may additionally be performed in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N′-dicyclohexylcarbodiimide, advantageously in the presence of a catalyst such as a N-hydroxy compound e.g. a N-hydroxytriazole such as 1-hydroxybenzotriazole. Alternatively, the acid may be reacted with a chloroformate, for example ethylchloroformate, prior to reaction with the amine of formula (3).

The esters of formula (3) and acids R⁶CO₂H are either known compounds or may be obtained from simpler compounds by one or more standard synthetic methods employing substitution, oxidation, reduction or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation, sulphonylation, nitration, formylation and coupling procedures. It will be appreciated that these methods may also be used to modify the compounds of formula (1) and the esters or formula (2) where appropriate functional groups exist in these compounds.

Thus, for example compounds of the invention and intermediates thereto may be prepared by alkylation, arylation or heteroarylation. For example compounds containing a L¹H or L³H group may be alkylated or arylated using a reagent R¹(Alk¹)_(r)X or R¹⁰(Alk³)_(q)X in which X is a leaving atom or group such as a halogen atom, e.g. a fluorine, bromine, iodine or chlorine atom or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy, e.g. p-toluenesulphonyloxy group.

The alkylation or arylation reaction may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran.

In another example, compounds containing a L¹H or -L³H group may be functionalised by acylation or thioacylation, for example by reaction with a reagent R¹(Alk¹)_(r)L¹X [wherein L¹ is a —C(O)—, —C(S)—, or —N(R⁸)C(S)— group], R¹⁰(Alk³)_(q)COX or R¹⁰(Alk³)_(q)NHCOX in the presence of a base, such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g. dimethylformamide, at for example ambient temperature, or by reaction with R¹(Alk¹)_(r)CO₂H or R¹⁰(Alk³)_(q)CO₂H or an activated derivative thereof, for example as described above for the preparation of esters of formula (3).

In a further example a compound may be obtained by sulphonylation of a compound where R¹(Alk¹)_(r)L¹)s is an —OH group by reaction with a reagent R¹(Alk¹)_(r)L¹Hal [in which L¹ is —S(O)— or —SO₂— and Hal is a halogen atom such as a chlorine atom] in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature.

In another example, a compound where R¹(Alk¹)_(r)(L¹)s is a -L¹H group, may be coupled with a reagent R¹ OH (where R¹ is other than a hydrogen atom) or R¹Alk¹OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl, diisopropyl- or dimethylazodicarboxylate to yield a compound containing a R¹ (Alk¹)_(r)O— group.

In a further example, ester groups —CO₂Alk⁵ in the compounds may be converted to the corresponding acid [—CO₂H] by acid- or base-catalysed hydrolysis depending on the nature of the group Alk⁵ using the reactants and conditions described above for the hydrolysis of esters of formula (2).

In another example, —OR¹² groups [where R¹² represents an alkyl group such as methyl group] in compounds of formula (1) may be cleaved to the corresponding alcohol —OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around −78° C.

Alcohol [—OH] groups may also be obtained by hydrogenation of a corresponding —OCH₂R¹² group (where R¹² is an aryl group) using a met al catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, —OH groups may be generated from the corresponding ester [—CO₂Alk⁵] or aldehyde [—CHO] by reduction, using for example a complex met al hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.

Aminosulphonylamino [—NHSO₂NH₂] groups in the compounds may be obtained, in another example, by reaction of a corresponding amine [—NH₂] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

In a further example amine (—NH₂) groups may be alkylated using a reductive alkylation process employing an aldehyde and a borohydride, for example sodium triacetoxyborohyride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.

In a further example, amine [—NH₂] groups in compounds of formula (1) may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [—NO₂] group may be reduced to an amine [—NH₂], for example by catalytic hydrogenation using for example hydrogen in the presence of a met al catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol e.g. methanol, or by chemical reduction using for example a met al, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

Aromatic halogen substituents in the compounds may be subjected to halogen-met al exchange with a base, for example a lithium base such as n-butyl or t-butyl lithium, optionally at a low temperature, e.g. around −78° C., in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using dimethylformamide as the electrophile; a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile.

In another example, sulphur atoms in the compounds, for example when present in a linker group L¹ or L³ may be oxidised to the corresponding sulphoxide or sulphone using an oxidising agent such as a peroxy acid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.

N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C., or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate base in a suit able solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.

The following Examples illustrate the invention. All temperatures are in ° C. The following abbreviations are used:

EDC—1-(3-dimethylaminopropyl)3-ethycarbodiimide;

DMF—dimethylformamide;

DMSO—dimethylsulphoxide;

HOBT—1-hydroxybenzotriazole;

THF—tetrahydrofuran;

TFA—trifluoroaceticacid;

NMM—N-methylmorpholine;

DCM—dichloromethane;

Ph—phenyl;

BOC—tert-butoxycarbonyl;

EtOAc—ethyl acetate;

MeOH—methanol;

LDA—lithium diisopropylamide

tyr—tyrosine;

Ar—aryl;

HetAr—heteroaryl;

pyr—pyridine;

thiopro—thioproline;

Bu—butyl

Me—methyl

Intermediate 1 N-BOC-D-thioproline-(O-2,6-dichlorobenzyl)-L-tyrosine methyl ester

EDC (634 mg, 3.3mmol) was added to a solution of N-BOC-D-thioproline (699 mg, 3mmol), (O-2,6-dichlorobenzyl)-L-tyrosine methyl ester hydrochloride (1.17g, 3mmol), HOBT (446 mg, 3.3mmol) and NMM (692 μl, 6.3 mmol) in DCM (30 ml). The mixture was stirred for 4 h at room temperature then diluted with DCM (20 ml) and washed with dilute hydrochloric acid (1 M, 50 ml), saturated NaHCO₃ solution (50 ml) and water (50 ml). The DCM solution was dried (Na₂SO₄) and evaporated under reduced pressure to give the title compound (1.70 g) as a white foam. δH (DMSO-d₆, 300K) 8.41 (1H, br s, CONH), 7.57-7.43 (3H, m, ArH), 7.15 (2H, d, J 8.5 Hz, ArH), 6.96 (2H, d, J 8.6 Hz, ArH), 5.18 (2H, s, OCH₂Ar), 4.6-4.4 (2H, br m, CHαthiopro +CHαtyr), 4.56 (1H, d, J 8.9 Hz, NCH _(A)H_(B)S), 4.23 (1H, d, J 9.0 Hz, NCH_(A) H _(B)S), 3.64 (3H, s, CO₂Me), 3.19 (1H, dd, J 7.5, 11.5 Hz, CHCH _(A)H_(B)S), 3.04 (1H, dd, J 5.1, 13.7 Hz, CHCH _(A) H _(B)Ar), 2.85 (1H, dd, J 9.6, 13.7 Hz, CHCH _(A) H _(B)Ar), 2.7 (1H, br m, CHCH_(A) H _(B)S) and 1.33 (9H, br s, tBu); m/z (ESI, 60V) 591 M ⁺+Na).

Intermediate 2 Methyl (2R)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}-2-({[(4S)-3-(tert-butoxycarbonyl)-1,3-thiazolan-4-yl]carbothioyl}amino)porpanoate

Lawesson's reagent (202 mg, 0.5 mmol) was added to a solution of Intermediate 1 (569 mg, 1 mmol) in THF (10 ml). The suspension was refluxed for 3.5 h to give a yellow solution. The solvent was removed under reduced pressure and the residue purified by column chromatography (SiO₂; DCM) to give the title compound as a colourless gum (345 mg, 59%). δH (DMSO-d₆, 300K) 10.3 (1H, br s, CSNH), 7.57-7.42 (3H, m, ArH), 7.17 (2H, d, J 8.3 Hz, ArH), 6.96 (2H, d, J8.6 Hz, ArH), 5.27 (1H, br s, CHαthiapro), 5.18 (2H, s, OCH₂Ar), 4.88 (1H, br s, CHαtyr), 4.65 (1H, d, J 9.1 Hz, NCH _(A)H_(B)S) 4.37 (1H, d, J 9.2 Hz, NCH_(A) H _(B)S), 3.66 (3H, s, CO₂Me), 3.33-3.27 (1H, m, CHCH _(A)H_(B)S), 3.18 (1H., dd, J5.5, 14.0 Hz, CHCH _(A)H_(B)Ar), 3.05 (1H, dd, J 9.1, 14.0 Hz, CHCH_(A) H _(B)Ar), 2.73 (1H, br m, CHCH_(A) H _(B)S) and 1.31 (9H, br s, CMe₃); m/z (ESI, 60V) 605 (M⁺Na).

Intermediate 3 Methyl (2R)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}-2-{[(4S)-1,3 thiazolan-4-ylcarbothioyl]amino}propanoate hydrochloride

Anhydrous HCl gas was bubbled through a solution of Intermediate 2 (324 mg, 0.554 mmol) in EtOAc (10 ml) for one minute. After 30 min the solvent was removed under reduced pressure to give the title compound (292 mg) as a yellow solid. δH (DMSO-d₆, 300K) 11.19 (1 H, br d, J 7.3 Hz, CSNH), 7.57-7.43 (3H, m, ArH), 7.20 (2H, d, J 8.6 Hz, ArH), 6.98 (2H, d, J 8.6 Hz, ArH), 5.21-5.18 (1H, m, CHαtyr), 5.18 (2H, s, OCH₂Ar), 4.65 (1H, br t, J 7.7 Hz, CHαthiopra), 4.33 (1H, d, J 9.6 Hz, NCH _(A)H_(B)S), 4.28 (1H, d, J 9.6 Hz, NCH_(A) H _(B)S), 3.69 (3H, s, CO₂Me), 3.33 (1H, dd, J 7.1, 11.2 Hz, CHCH _(A)H_(B)S), 3.23 (1H, dd, J 5.2, 13.9 Hz, CH _(A)H_(B)Ar), 3.08 (1H, dd, J 9.8, 13.9 Hz, CH_(A) H _(B)Ar) and 2.61 (1H, dd, J 8.5, 11.2 Hz, CHCH_(A) H _(B)S); m/z (ESI, 60V) 485 (M⁺+1).

Intermediate 4 Methyl (2R)-2-({[(4S)-3-acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoate

Acetic anhydride (57 μl, 0.602 mmol) was added to a solution of Intermediate 3 (285 mg, 0.547 mmol) and NMM (60 μl, 0.547 mmol) in DCHM(10 ml). The mixture was stirred at room temperature for 3 h, diluted with DCM (100 ml), washed with dilute HCI (aqueous) (20 ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by column chromatography (SiO₂; EtOAc/hexane, 50:50 to 75:25) to give the title compound as a colourless oil (285 mg). δH (DMSO-d₆, 400K) 9.67 (1H, br s, CSNH), 7.51-7.39 (3H, m, ArH), 7.17 (2H, d, J 8.6 Hz, ArH), 6.97 (2H, d, J 8.6 Hz, ArH), 5.36 (1H, dd, J 5.8, 8.1 Hz, CHαtyr), 5.26 (2H, s, OCH₂Ar), 5.15 (1H, dd, J 4.6, 7.4 Hz, CHαthiopro), 4.83 (1H, d, J 9.3 Hz, NCH _(A)H_(B)S), 4.51 (1H, d, J 9.3 Hz, NCH_(A) H _(B)S), 3.68 (3H, s, CO₂Me), 3.39 (1 H, dd, J 7.5, 11.7 Hz, CHCH _(A)H_(B)S), 3.21 (1 H, dd, J 5.8, 14.2 Hz, CH _(A)H_(B)Ar), 3.13 (1H, dd, J 8.3, 14.2 Hz, CH_(A) H _(B)Ar), 3.07 (1H, dd, J 4.8, 11.7 Hz, CHCH_(A) H _(B)S) and 1.95 (3H, s, NCOCH₃); m/z (ESI, 60V) 527 (M⁺+1).

EXAMPLE 1 (A) (2R)-2-({[(4S)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid (B) (2R)-2-({[(4R)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid

Lithium hydroxide monohydrate (25 mg, 0.58 mmol) was added to a solution of Intermediate 4 (280 mg, 0.531 mmol) in THF (5 ml) and water (5 ml). After 1 h at room temperature the THF was removed under reduced pressure, the aqueous residue acidified and extracted with DCM (2×50 ml). The extracts were dried (Na₂SO₄) and evaporated under reduced pressure to give a fluffy white solid (233 mg). Separation by preparative HPLC gave the title compound, diastereoisomer A δH (DMSO-d₆, 390K) 955 (1H, br s, CSNH), 7.51-7.39 (3H, m, ArH), 7.17 (2H, d, J 8.7 Hz, ArH), 6.96 (2H, d, J 8.7ArH), 5.26 (2H, s, OCH₂Ar), 5.26-5.22 (1H, m, Cαtyr), 5.15 (1H, dd, J 4.8, 7.4 Hz, CHαthiapro), 4.84 (1 d, J 9.3 Hz, NCH _(A)H_(B)S), 4.50 (1 H, d, J 9.3 Hz, NCH_(A) H _(B)S), 3.38 (1H. dd J 7.5, 11.7 Hz, CHCH _(A)H_(B)S) 3.25 (1H, dd, J 5.4, 14.3 Hz, CH _(A)H_(B)Ar), 3.06 (1H, dd, J 4.7, 11.7 Hz, CHCH_(A) H _(B)S), and 1.94 (3H, s, NCOCH₃); m/z (ESI, 60V), 513 (M ⁺+1). and the title compound, diastereoisomer B δH (DMSO-d₆, 390K) 9.49 (1 H, br s, CSHN) 7.51-7.39 (3H, m, ArH), 7.20 (2H, d, J 8.6 Hz, ArH), 6.95 (2H, d, J 8.6 Hz, ArH), 5.30-5.25 (1H, m, CHαtyr), 5.25 (2H, s, OCH₂Ar), 5.16 (1H, dd, J 4.3, 7.5 Hz, CHαthiopro), 4.81 (1H, d, J 9.4 Hz, NCH _(A)H_(B)S), 4.46 (1H, d, J 9.4 Hz, NCH_(A) H _(B)S), 3.45 (1H, dd, J 7.5, 11.7 Hz, CHCH _(A)H_(B)S), 3.26 (1H, dd, J 5.5, 14.3 Hz, CH _(A)H_(B)Ar), 3.20-3.10 (2H, m, CH_(A) H _(B)Ar+CHCH_(A) H _(B)S) and 1.93 (3H, s, NCOCH₃); m/z (ESI, 60V) 513 (M⁺+1).

The following assays can be used to demonstrate the potency and selectivity of the compounds according to the invention. In each of these assays an IC₅₀ value was determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition of cell adhesion where 100%=adhesion assessed in the absence of the test compound and 0%=absorbance in wells that did not receive cells.

α₄β₁ Intearin-dependent Jurkat Cell Adhesion to VCAM-Ig

96 well NUNC plates were coated with F(ab)₂ fragment goat anti-human IgG Fcγ-specific antibody [Jackson Immuno Research 109-006-098: 100 μl at 2 μg/ml in 0.1M NaHCO₃, pH 8.4], overnight at 4°. The plates were washed (3×) in phosphate-buffered saline (PBS) and then blocked for 1 h in PBS/1% BSA at room temperature on a rocking platform. After washing (3× in PBS) 9 ng/ml of purified 2d VCAM-Ig diluted in PBS/1% BSA was added and the plates left for 60 minutes at room temperature on a rocking platform. The plates were washed (3× in PBS) and the assay then performed at 37° for 30 min in a total volume of 200 μl containing 2.5×10⁵ Jurkat cells in the presence or absence of titrated test compounds.

Each plate was washed (2×) with medium and the adherent cells were fixed with 100 μl methanol for 10 minutes followed by another wash. 100 μl 0.25% Rose Bengal (Sigma R⁴⁵⁰⁷) in PBS was added for 5 minutes at room temperature and the plates washed (3×) in PBS. 100 μl 50% (v/v) ethanol in PBS was added and the plates left for 60 min after which the absorbance (570 nm) was measured.

α₄β₇ Integrin-dependent JY Cell Adhesion to MAdCAM-Ig

This assay was performed in the same manner as the α₄β₁ assay except that MAdCAM-Ig (150 ng/mJ ) was used in place of 2d VCAM-Ig and a sub-line of the β-lympho blastoid cell-line JY was used in place of Jurkat cells. The IC₅₀ value for each test compound was determined as described in the α₄β₁ integrin assay.

α₅β₁ Intearin-dependent K562 Cell Adhesion to Fibronectin

96 well tissue culture plates were coated with human plasma fibronectin (Sigma F0895) at 5 μg/ml in phosphate-buffered saline (PBS) for 2 hr at 37° C. The plates were washed (3× in PBS) and then blocked for 1 h in 100 μl PBS/1% BSA at room temperature on a rocking platform. The blocked plates were washed (3× in PBS) and the assay then performed at 37° C. in a total volume of 200 μl containing 2.5×10⁵ K562 cells, phorbol-12-myristate-13-acetate at 10 ng/ml, and in the presence or absence of titrated test compounds. Incubation time was 30 minutes. Each plate was fixed and stained as described in the α₄β₁ assay above.

α_(m)β₂-dependent Human Polymorphonuclear Neutrophils Adhesion to Plastic

96 well tissue culture plates were coated with RPMI 1640/10% FCS for 2 h at 37° C. 2×10⁵ freshly isolated human venous polymorphonuclear neutrophils (PMN) were added to the wells in a total volume of 200 μl in the presence of 10 ng/ml phorbol-12-myristate-13-acetate, and in the presence or absence of test compounds, and incubated for 20 min at 37° C. followed by 30 min at room temperature. The plates were washed in medium and 100 μl 0.1% (w/v) HMB (hexadecyl trimethyl ammonium bromide, Sigma H₅₈₈₂) in 0.05M potassium phosphate buffer, pH 6.0 added to each well. The plates were then left on a rocker at room temperature for 60 min. Endogenous peroxidase activity was then assessed using tetramethyl benzidine (TMB) as follows: PMN lysate samples mixed with 0.22% H₂O₂ (Sigma) and 50 μg/ml TMB (Boehringer Mannheim) in 0.1M sodium acetate/citrate buffer, pH 6.0 and absorbance measured at 630 nm.

αIIb/β₃-dependent Human Platelet Aggregation

Human platelet aggregation was assessed using impedance aggregation on the Chronolog Whole Blood Lumiaggregometer. Human platelet-rich plasma (PRP) was obtained by spinning fresh human venous blood anticoagulated with 0.38% (v/v) tri-sodium citrate at 220×g for 10 min and diluted to a cell density of 6×10⁸/ml in autologous plasma. Cuvettes contained equal volumes of PRP and filtered Tyrode's buffer (g/liter: NaCl 8.0; MgCl₂.H₂O 0.427; CaCl₂ 0.2; KCl 0.2; D-glucose 1.0; NaHCO₃ 1.0; NaHPO₄.2H₂O 0.065). Aggregation was monitored following addition of 2.5 μM ADP (Sigma) in the presence or absence of inhibitors.

In the above assays the compounds of the invention generally have IC₅₀ values in the α₄β₁ and α₄β₇ assays of 1 μM and below. In the other assays featuring α integrins of other subgroups the same compounds had IC₅₀ values of 50 μM and above thus demonstrating the potency and selectivity of their action against α₄ integrins. 

What is claimed is:
 1. A compound of formula (1):

wherein R¹ is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Alk¹ is an alkyl group; L¹ is an oxygen atom; r is zero or the integer 1; s is the integer 1; R² and R³, which may be the same or different, is each a hydrogen or halogen atom, a hydroxyl or nitro group, or a straight or branched alkyl, haloalkyl, alkoxy, or haloalkoxy group; Alk² is a straight or branched alkylene chain; m is zero or an integer 1; R⁴ is a hydrogen atom or a methyl group; R⁵ is a hydrogen atom or a straight or branched alkyl group; R⁶ is a group —(CH₂)_(t)R⁷ in which t is zero or the integer 1 and R⁷ is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; R is a carboxylic acid (—CO₂H) or a derivative thereof; and the salts, solvates and hydrates thereof; with the proviso that at least one of R¹ or R⁷ is a heterocycloaliphatic, polyheterocycloaliphatic, or heteroaromatic group.
 2. A compound according to claim 1 wherein R is a —CO₂H group.
 3. A compound according to claim 1 wherein Alk² is a —CH₂— chain and m is an integer
 1. 4. A compound according to claim 1 wherein R⁴ and R⁵ is each a hydrogen atom.
 5. A compound according to claim 1 wherein R¹ is an optionally substituted aromatic or heteroaromatic group.
 6. A compound according to claim 5 wherein R¹ is an optionally substituted phenyl, pyridyl or pyrimidinyl group.
 7. A compound according to claim 1 wherein R⁶ is an optionally substituted heterocycloaliphatic a romatic or heteroaromatic group.
 8. A compound according to claim 7 wherein R⁶ is an optionally substituted pyrrolidinyl, thiazolidinyl, phenyl or pyridyl group.
 9. A compound according to claim 1 which is 2-({[3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid; and the salts, solvates and hydrates thereof.
 10. A compound according to claim 9 which is selected from the group consisting of: (2R)-2-({[(4S)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-(dichlorobenzyl)oxy]phenyl}propanoic acid; and (2R)-2-({[(4R)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid; and the salts, solvates and hydrates thereof.
 11. A compound according to claim 10 which is (2R)-2-({[(4S)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid; and the salts, solvates and hydrates thereof.
 12. A compound according to claim 10 which is (2R)-2-({[(4R)-3-Acetyl-1,3-thiazolan-4-yl]carbothioyl}amino)-3-{4-[(2,6-dichlorobenzyl)oxy]phenyl}propanoic acid; and the salts, solvates and hydrates thereof.
 13. A pharmaceutical composition comprising a compound of formula (1):

wherein R¹ is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Alk¹ is an alkyl group; L¹ is an oxygen atom; r is zero or the integer 1; s is the integer 1; R² and R³, which may be the same or different, is each a hydrogen or halogen atom, a hydroxyl or nitro group, or a straight or branched alkyl, haloalkyl, alkoxy, or haloalkoxy group; Alk² is a straight or branched alkylene chain; m is zero or an integer 1; R⁴ is a hydrogen atom or a methyl group; R⁵ is a hydrogen atom or a straight or branched alkyl group; R⁶ is a group —(CH₂)_(t)R⁷ in which t is zero or the integer 1 and R⁷ is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; R is a carboxylic acid (—CO₂H) or a derivative thereof; and the salts, solvates and hydrates thereof; together with one or more pharmaceutically acceptable carriers, excipients or diluents; with the proviso that at least one of R¹ or R⁷ is a heterocycloaliphatic, polyhetcrocycloaliphatic, or heteroaromatic group.
 14. A pharmaceutical composition according to claim 13 wherein R¹ is an optionally substituted aromatic or heteroaromatic group.
 15. A method for the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role, comprising administering to a mammal suffering from such a disease or disorder a therapeutically effective amount of a compound of formula (1):

wherein R¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Alk¹ is an alkyl group; L¹ is an oxygen atom; r is zero or the integer 1; s is the integer 1; R² and R³, which may be the same or different, is each a hydrogen or halogen atom, a hydroxyl or nitro group, or a straight or branched alkyl, haloalkyl, alkoxy, or haloalkoxy group; Alk² is a straight or branched alkylene chain; m is zero or an integer 1; R⁴ is a hydrogen atom or a methyl group; R⁴ is a hydrogen atom or a straight or branched alkyl group; R⁶ is a group —(CH₂)_(t)R⁷ in which t is zero or the integer 1 and R⁷ is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; R is a carboxylic acid (—CO₂H) or a derivative thereof; and the salts, solvates and hydrates thereof; with the proviso that at least one of R¹ or R⁷ is heterocycloaliphatic, polyheterocycloaliphatic, or heteroaromatic group.
 16. A method according to claim 15 wherein said disease or disorder is selected from the group consisting of inflammatory arthritis, multiple sclerosis, allograft rejection, diabetes, inflammatory dermatoses, asthma and inflammatory bowel disease.
 17. A method according to claim 15 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis vasculitis and polydermatomyositis.
 18. A method according to claim 15 wherein said inflammatory dermatoses are selected from the group consisting of psoriasis and dermatitis.
 19. A method for inhibiting, in a mammal, the binding of α4 integrins to the ligands thereof, comprising administering to the mammal an effective amount of a compound of formula (1):

wherein R¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Alk¹ is an alkyl group; L¹ is an oxygen atom; r is zero or the integer 1; s is the integer 1; R² and R³, which may be the same or different, is each a hydrogen or halogen atom, a hydroxyl or nitro group, or a straight or branched alkyl, haloalkyl, alkoxy, or haloalkoxy group; Alk² is a straight or branched alkylene chain; m is zero or an integer 1; R⁴ is a hydrogen atom or a methyl group; R⁵ is a hydrogen atom or a straight or branched alkyl group; R⁶ is a group —(CH₂)_(t)R⁷ in which t is zero or the integer 1 and R⁷ is an optionally substituted polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; R is a carboxylic acid (—CO₂H) or a derivative thereof; and the salts, solvates and hydrates thereof; with the proviso that at least one of R¹ or R⁷ is a heterocycloaliphatic, polyheterocycloaliphatic, or heteroaromatic group.
 20. A method according to claim 19 wherein the α4 integrins are selected from the group consisting of α4β1 and α4β7 integrins. 